calcaftor
Pre-clinical- Indications
- Cystic fibrosis
Company intelligence / Profile preview
Calista Therapeutics Inc
Lincoln, Rhode Island, United Statesventureradar.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Preclinical
01
Overview
Calista Therapeutics is developing several peptide-based therapeutics including Calcaftor for cystic fibrosis and MT-002 for neurotrophic keratitis. Their lead drug AT010 targets cystic fibrosis by stabilizing defective ion channels in lung epithelial membranes.
- Therapeutic areas
- PulmonologyOphthalmologyNeurology
- Modalities
- Peptide-based therapeuticsInhaled peptide drugs
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Calista Therapeutics Inc.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Calista Therapeutics Inc.